|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | Outsourced Pharma Chief Editor Louis Garguilo says he's sure some readers will smirk at this headline. CDMOs are running a business; they may attempt to treat all customers equally, but they focus where the most financial gain is. Nonetheless, according to a very experienced outsourcing professional, there's nothing humorous here at all. | |
|
|
| Breaking The Cell Therapy Manufacturing Bottleneck | Webinar | BlueWhale Bio | Discover the potential of T1 cell-derived nanoparticles (CDNPs) to accelerate T-cell activation. See how CDNPs’ unique mechanism of mimicking physiological immune stimulation positions them for broad use. |
|
|
| The Key To Viral Vector Success | White Paper | By Kristine Siemer, Ayan Dey, Amy Villanueva, Ricardo Correa, and Jason Rodriguez, MilliporeSigma | Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing. |
|
|
| Stopper Migration In Frozen Pre-Filled Syringes | White Paper | By Jayasree M. Srinivasan, Ph.D., Simtra BioPharma Solutions | Review a semi-automated method for dynamically assessing plunger migration under controlled variations in temperature and pressure, utilizing computer vision tools. |
|
|
|
| Put Your AAV On The Fast-Track To The Clinic | White Paper | Catalent | Review an innovative method to fast-tracking AAVs through a platform approach that easily scales as the project progresses to late-stage GMP production and to market. |
|
|
|
|
|
| The Challenges Of Moving A Bioconjugate From Clinic To Market | Article | By Iwan Bertholjotti and Dr. Bernhard Stump, Lonza | Working with a partner that provides a one-stop shop for bioconjugate development and manufacturing helps prevent missteps that threaten the delivery of life-saving drugs to patients who need them. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
